https://www.selleckchem.com/pr....oducts/Gefitinib.htm
In rectal cancer, prediction of tumor response and pathological complete response (pCR) to neoadjuvant treatment could contribute to refine selection of patients who might benefit from a delayed- or no-surgery approach. The aim of this study was to explore the association of clinical and molecular characteristics of rectal cancer with response to neoadjuvant treatment and to compare patient survival according to level of response. Resected rectal cancer patients were selected from a population-based cohort study. Molecular tumor marke